NCCN guidelines advocate wider use of colony-stimulating factor.
McNeil
Caroline
C
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003115:Colony-Stimulating Factors / Q000627:therapeutic use*; D032921:Consensus; D011307:Drug Prescriptions / Q000592:standards / Q000706:statistics & numerical data; D019317:Evidence-Based Medicine; D005334:Fever / Q000209:etiology / Q000517:prevention & control; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy*; D011092:Polyethylene Glycols; D017410:Practice Guidelines as Topic; D011994:Recombinant Proteins; D018570:Risk Assessment; D014481:United States
D000970:Antineoplastic Agents; D003115:Colony-Stimulating Factors; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D000069585:Filgrastim